Cargando...
Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer
The therapies available for prostate cancer patients whom progress from hormone-sensitive to castration resistant prostate cancer include both systemic drugs, including docetaxel and cabazitaxel, and drugs that inhibit androgen signaling such as enzalutamide and abiraterone. Unfortunately, it is est...
Gardado en:
| Publicado en: | Asian J Urol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Second Military Medical University
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5477778/ https://ncbi.nlm.nih.gov/pubmed/28642838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajur.2016.08.001 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|